- Home
- JTAI vs MBIO Comparison
JTAI vs MBIO Comparison
Compare JTAI & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JTAI | MBIO |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 7.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | JTAI | MBIO |
|---|---|---|
| Price | $0.12 | $0.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | ★ 32.7M | 148.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.53 |
| 52 Week High | $6.35 | $7.00 |
Technical Indicators
Market Signals| Indicator | JTAI | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 30.79 | 50.22 |
| Support Level | $0.09 | $0.91 |
| Resistance Level | $1.15 | $1.10 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 30.00 | 64.04 |
Price Performance
Historical ComparisonAbout JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.